On Nov 06, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $91 to $106.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $81 to $106.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $84 to $100.
Baird analyst Jack Allen maintains with a buy rating, and adjusts the target price from $77 to $106.
Needham analyst Gil Blum maintains with a buy rating, and maintains the target price at $96.
William Blair analyst Sami Corwin maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The expectations for Arcellx's anito-cel have been enhanced due to the promising initial results from the iMMagine-1 Phase 2 trial involving relapsed/refractory multiple myeloma patients. There is a considerable opportunity for market share capture, starting with treatment in later-stage patients and potentially extending to earlier stages if the current clinical outcomes are maintained.
Recent abstracts presenting initial Phase 2 data and extended Phase 1 data reinforce the pivotal-stage anito-cel's solid profile and its regulatory standing in the treatment of multiple myeloma. Despite a dip in share value, this could be interpreted as a 'sell the news' reaction following a substantial pre-abstract appreciation. It is now anticipated that anito-cel will secure a more significant share of the peak market and has increased chances of success.
The firm expressed incremental optimism following the release of updated clinical data. The publication of ASH abstracts, which included initial data from the registrational IMMagine-1 study, contributed to this positive outlook.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
